Change in LVESV (mL) | HR death, Tx or LVAD | HR death/HF hospitalisation | |
---|---|---|---|
LBBB present | −14.5 (−29.6 to 0.6) | 0.35 (0.15 to 0.82) | 0.63 (0.32 to 1.24) |
LBBB absent | −3.2 (−17.2 to 10.8) | 0.66 (0.32 to 1.36) | 0.66 (0.37 to 1.18) |
Interaction p value | 0.33 | 0.17 | 0.69 |
QRS >150 ms | −17.9 (−34.4 to −1.4) | 0.31 (0.14 to 0.69) | 0.28 (0.14 to 0.55) |
QRS <150 ms | −6.2 (−18.6 to 6.1) | 0.67 (0.30 to 1.51) | 0.92 (0.50 to 1.67) |
Interaction p value | 0.08 | 0.23 | 0.012 |
Overall effect | −10.5 (−20.5 to −0.5) | 0.53 (0.31 to 0.91) | 0.61 (0.40 to 0.92) |
Overall p value | 0.04 | 0.02 | 0.02 |
*Estimated effect (95% CI) adjusted for LBBB or QRS ≥150 ms, age, gender, HF aetiology, systolic blood pressure, diabetic status, serum creatinine, β-blocker usage, ACE inhibitor or ARB usage, aldosterone-antagonist usage, LVESV and EF.
ARB, angiotensin receptor blocker; EF, ejection fraction; HF, heart failure; HR, heart rate; LBBB, left bundle-branch block; LVAD, left ventricular assist device; LVESV, left ventricular end-systolic volume; Tx, transplant.